InMed Pharmaceuticals

Alzheimer’s disease presents a major unmet medical need with an estimated 1 in 9 people aged 65+ affected.

InMed's INM-901 is a novel drug candidate that has demonstrated that it may address multiple pathologies related to disease progression.

In this video, InMed's CEO Eric A. Adams goes over the INM-901 program and details of the preclinical studies as well as 's pathology: https://ow.ly/nQkS50SKyXU

$INM

Video Presentation: InMed's INM-901 is a Potential Multi-factorial Approach to Treating Alzheimer's Disease - InMed Pharmaceuticals Watch this video presentation by InMed's CEO, Eric A. Adams, as he shares data on the unique pharmacological effects of INM-901, a drug candidate for the treatment of Alzheimer's disease.

InMed's CEO, Eric A. Adams, and Senior VP of Preclinical Research and Development, Dr. Eric Hsu, will be attending the Association International Conference in Philadelphia, PA July 28-Aug 1.

The InMed team will be sharing the latest preclinical results of Alzheimer's drug candidate INM-901.

More about InMed's INM-901 Alzheimer's program: https://ow.ly/6WQj50SKnHf

$INM

In this short video, InMed's CEO Eric A. Adams shares a summary of the preclinical results of INM-901, a drug candidate for the potential treatment of 's disease.

Watch video: https://ow.ly/wPjA50SKk65

$INM

InMed's INM-901 for Alzheimer's Disease - Preclinical Data Summary - InMed Pharmaceuticals InMed's CEO, Eric A. Adams, provides a summary of the preclinical studies of INM-901, the company's drug candidate in the potential treatment of Alzheimer's disease.

InMed's INM-901 is a small molecule drug candidate for disease.

As a small molecule, INM-901 appears to safely and effectively cross the blood/brain barrier, which is essential to any compound targeting diseases such as ’s and could greatly reduce the treatment costs and the compliance challenges associated with large molecule antibody therapies.

More in this FierceBiotech article: https://ow.ly/5i4r50SHIiH

$INM

InMed’s INM-901 Demonstrates Potential as a Multi-factorial Approach to Treating Alzheimer’s Disease InMed Pharmaceuticals (Nasdaq:INM) recently released preclinical data indicating its

INM-901 May Address Multiple Pathologies Related to ’s Disease

"InMed’s in vitro and in vivo studies demonstrated encouraging effects in a well-characterized Alzheimer’s disease preclinical model. In this study, InMed’s INM-901 demonstrated neuroprotective effects by reducing cell death in an amyloid-beta-induced cytotoxicity study and demonstrated an ability to promote the growth and extension of neurites ( ), an essential component of cell-to-cell communication. INM-901 also demonstrated reduced neuroinflammation and showed improvement in behavior, cognitive function and memory in in vivo studies. These promising early data of INM-901 represent the potential for disease-modifying effects as well as the potential to reverse neuronal damage associated with ."

More in this FierceBiotech article: https://ow.ly/gnAZ50SIuzn

$INM

In an amyloid-beta peptide-induced toxicity model, InMed's INM-901 demonstrated neuroprotective effects, protecting neuronal cells from damage and death. Neuroprotection of neuronal cells is recognized as an important component of slowing the progression of disease.

In addition to neuroprotective effects, preclinical studies of INM-901 have demonstrated reduced neuroinflammation, extension of neurites which may signify improvement in neuronal function, and improvement in locomotor activity, cognition and memory.

Watch video here: https://ow.ly/J2Ok50SHIGn

$INM

Video Presentation: InMed's INM-901 is a Potential Multi-factorial Approach to Treating Alzheimer's Disease - InMed Pharmaceuticals Watch this video presentation by InMed's CEO, Eric A. Adams, as he shares data on the unique pharmacological effects of INM-901, a drug candidate for the treatment of Alzheimer's disease.

Study Reveals InMed’s INM-901 Targets CB1, CB2 and PPAR Pathways

and are part of the system which is involved in almost every facet of the body’s functioning and plays a key role in brain function. Activation of these receptors may address factors influencing disease progression.

Studies of INM-901 demonstrate that this small molecule drug candidate acts as a preferential signaling ligand for CB1/CB2 and impacts the peroxisome poliferator-activated receptor ( ) signalling pathway.

Read more in this FierceBiotech article: https://ow.ly/rlEs50SHxqK

$INM

InMed’s INM-901 Demonstrates Potential as a Multi-factorial Approach to Treating Alzheimer’s Disease InMed Pharmaceuticals (Nasdaq:INM) recently released preclinical data indicating its

Article: InMed’s INM-901 Demonstrates Potential as a Multi-factorial Approach to Treating Alzheimer’s Disease

Read about INM-901's 's disease studies, what leads to the progression of and the disease impact and prevalence.

Article in FierceBiotech: https://ow.ly/lHNc50SHqq6

$INM

InMed’s INM-901 Demonstrates Potential as a Multi-factorial Approach to Treating Alzheimer’s Disease InMed Pharmaceuticals (Nasdaq:INM) recently released preclinical data indicating its

INM-901 is a small molecule drug candidate being studied for the potential treatment of 's disease. Small molecules can cross the blood-brain barrier, which is important when targeting diseases such as , and are typically better suited for multiple drug delivery systems, which may reduce barriers such as cost and accessibility.

More on INM-901: https://ow.ly/nMiY50SFy5Y

$INM

An earlier in vitro 's disease study conducted by InMed in collaboration with UBC Faculty of Pharmaceutical Sciences' Dr. Ujendra Kumar demonstrated how InMed's compounds reduced amyloid toxicity and tau protein expression while enhancing neuronal cell growth, all considered to be important targets in the potential treatment of diseases such as .

These promising studies led to the launch of INM-901, a drug candidate being developed for the treatment of Alzheimer's disease.

Scientific poster here: https://ow.ly/vLlE50SBTNM

$INM

Scientific Poster: Neurodegenerative Disease Study Presented at Canadian Neuroscience Meeting - InMed Pharmaceuticals Scientific Poster: “Cannabinoids modulate cytotoxicity and neuritogenesis in Amyloid-beta-treated neuronal cells” The InMed-sponsored study demonstrated the ability of a specific rare cannabinoid (“pCBx”) in InMed’s 900 Series library of potential candidates to reduce amyloid toxicity and ...

In this video, InMed's CEO Eric A. Adams talks about INM-901, a drug candidate with a potential multifactorial approach to treating 's disease. He presents INM-901's preclinical data, receptor interactions, pathology and the prevalence of the disease.

Watch presentation: https://ow.ly/JEsH50SBTeC

$INM

Video Presentation: InMed's INM-901 is a Potential Multi-factorial Approach to Treating Alzheimer's Disease - InMed Pharmaceuticals Watch this video presentation by InMed's CEO, Eric A. Adams, as he shares data on the unique pharmacological effects of INM-901, a drug candidate for the treatment of Alzheimer's disease.

Study indicates that InMed's INM-089 is a preferential signaling agonist of and receptors. Activation of CB1 and CB2 receptors has been shown to protect cells from damage and death.

INM-089 is a small molecule drug candidate being studied for the potential treatment of age-related degeneration . Preclinical studies indicate neuroprotection of photoreceptors of the eye and improved integrity of the retinal pigment epithelium and thickness of outer nuclear layer - important aspects of preserving visual acuity.

Learn more: https://ow.ly/hp3A50SBJ6y

$INM

There are several pathological factors contributing to the development and progression of 's disease. While amyloid-beta plaque build-up is a known factor, researchers are looking into the impact of neuroinflammation and synaptic dysfunction as key contributors of disease progression.

Read more in this Drug Discovery article: https://ow.ly/BxYV50SBJIa

$INM

Cannabinoids Show Promise As New Treatment For Alzheimer's Disease Cannabinoids and their innate interaction with the endocannabinoid system, specifically with neuronal functioning, present an attractive therapeutic pathway for Alzheimer's disease, explains Eric Hsu, Ph.D., senior vice president of preclinical research and development at InMed Pharmaceutical...

InMed's INM-089 demonstrates improved pigment epithelium integrity.

One of the hallmarks of age-related degeneration is the deposits of , which is secreted by the RPE cells and can damage the integrity of the macula or back of the eye responsible for central vision. Most people over the age of 60 will have levels of drusen deposits. Hard drusen are small with well-defined borders and are associated with a lower risk of developing into AMD, whereas soft drusen are larger and cluster together and are associated with a higher risk of developing late-stage AMD, also known as geographic atrophy. Over time, soft drusen can lead to RPE detachments and damage the outer retina and cause central vision loss.

In an in vivo study conducted by InMed, it was demonstrated that INM-089 reduced extracellular autofluorescent (AF) deposits, including drusen.

Learn more about drug candidate INM-089 for dry AMD: https://ow.ly/uzah50SxsGe

$INM

InMed's Highlights:

Robust R&D with 3 candidates in , Age-related Degeneration &
-A successful Phase 2 program, currently seeking partnerships
-Library of proprietary analogs targeting diverse applications
A revenue generating subsidiary selling rare to the H&W industry
-Diverse product portfolio of non-intoxicating rare cannabinoids
-Consistent revenue growth including 278% YoY F2023 v F2022
Broad range of across molecules, manufacturing, formulations and methods of use

Snapshot: https://ow.ly/Uyli50SwfJJ

$INM &D

INM-089 is a small molecule drug candidate in preclinical studies for the treatment of age-related degeneration .

In vitro and in vivo studies of INM-089 have demonstrated:

-Neuroprotection of photoreceptors and improved photoreceptor function
-Improved integrity of the retinal pigment epithelium (RPE)
-Reduction of extracellular autofluorescent (AF) deposits, a hallmark of dry AMD
-Preservation of retinal function in the back of the eye
-Improved thickness of “outer nuclear layer” (ONL) of the retina where photoreceptors are located

Learn more about InMed's INM-089 for dry AMD: https://ow.ly/hMEX50SwfBI

$INM

's Disease is characterized by multiple pathologies.

In this Drug Discovery Online article, InMed's Dr. Eric Hsu discusses disease pathology, new , the potential to restore lost function and the need for a multi-factorial approach to treating this complex disease.

Read article: https://ow.ly/6aB850Sv1vz

$INM

Drug Discovery Online Article: Cannabinoids Show Promise As New Treatment For Alzheimer's Disease - InMed Pharmaceuticals InMed's Dr. Eric Hsu, is a guest columnist for Drug Discovery Online. In this article, he writes about Alzheimer's disease pathology, new anti amyloid-beta treatments, a need for multifactorial approach to this complex disease.

InMed's includes three programs:

-INM-901 for disease demonstrates reduced and -beta plaque and extension of in preclinical studies
-INM-089 for age-related degeneration improves photoreceptor function and thickness of outer nuclear layer of retina in preclinical studies
-INM-755 for epidermolysis bullosa demonstrated enhanced anti-itch activity in a Phase 2 clinical study

Learn about our pipeline: https://www.inmedpharma.com/

$INM

InMed's Eric A. Adams speaks at the Benzinga and Event. He talks about preclinical studies of INM-901 for 's disease and how this compound is demonstrating disease-modifying effects that may address multiple pathologies.

Watch on demand: https://www.inmedpharma.com/learn/inmed-presents-at-benzingas-healthcare-and-biotech-breakthroughs/

$INM

InMed Presents at Benzinga's Healthcare and Biotech Breakthroughs - InMed Pharmaceuticals InMed’s CEO Eric A. Adams featured at Benzinga’s Healthcare and Biotech Breakthroughs Event. Host Zunaid Suleman spoke with Eric Adams about InMed’s drug candidate INM-901 for Alzheimer’s disease and the exciting preclinical research that is showing how this small molecule compound is reduci...

June is and Brain Awareness Month.

Did you know more than 55 million people worldwide live with 's disease?

This destructive disease affects about 1 in 9 people aged 65 and older and there are limited treatment options available.

https://ow.ly/JHYj50SqyWX

$INM

How are CB1 and CB2 receptors involved in reducing amyloid-beta toxicity?

Studies indicate that cannabinoids, via CB1 and CB2 receptors, can reduce AB toxicity, decrease tau proteins and inflammatory response leading to improved neuronal viability.

An InMed study presented at Canadian Neuroscience Meeting demonstrates how specific cannabinoids modulated cytotoxicity and neuritogenesis in AB-treated neuronal cells.

More here: https://ow.ly/t6MK50SqyHB

$INM

www.inmedpharma.com

What is and how does it relate to disease?

Neuritogenesis is the growth and extension of neurites or branches of a neuron that enable communication between neurons. This process is reduced in patients with ’s, impacting brain processing. Restoring this process may reverse neuronal function loss caused by Alzheimer’s disease.

https://ow.ly/iEQG50Spv3y

$INM

The Dales Report REPLAY: InMed Pharmaceuticals and ’s Research

InMed’s CEO Eric A. Adams speaks about the company’s recent disease in vivo studies. He talks about current -beta treatments for Alzheimer’s as well as the need for new treatments to address the multiple pathologies related to this disease, including .

Watch podcast video: https://ow.ly/57Te50SozzV

$INM

The Dales Report: InMed Pharmaceuticals and Alzheimer’s Research - InMed Pharmaceuticals InMed’s CEO, Eric A. Adams, speaks with The Dales Report’s Shadd Dales and Anthony Varrell about the company’s recent Alzheimer’s disease in vivo studies. He talks about current amyloid-beta treatments for Alzheimer’s as well as the need for new treatments to address the multiple pathologi...

June is and Brain Awareness Month.

Did you know 1 in 9 people aged 65 and older live with 's disease?

While there are lifestyle preventive measures that can be taken to reduce the risk and slow progression of this destructive disease, there is also a major need for treatment options once the disease has developed.

https://ow.ly/fMcf50SlSPy

$INM

What is Age-related ? Does AMD cause blindness?

is a progressive eye disease that causes damage to the macula which is part of the retina at the back of the eye. The macula controls the sharp vision straight ahead of you, and damage to the macula affects a person’s central vision.

AMD is common amongst the elderly and is a leading cause of vision loss. While it does not cause complete blindness, those with AMD will find it difficult to read, drive or do simple things around the home.

https://ow.ly/gNXv50SlRXU

$INM

What is Age-related Macular Degeneration? Does AMD Cause Blindness? - InMed Pharmaceuticals Age-related macular degeneration (AMD) is a progressive eye disease that causes damage to the macula which is part of the retina at the back of the eye. The macula controls the sharp vision straight ahead of you, and damage to the macular affects a person’s central vision.

starts in one hour! 11am ET

InMed's CEO Eric A. Adams is presenting at the Benzinga & Breakthroughs Conference! He'll discuss InMed's new therapeutic approach in disease and .

Link to watch: https://ow.ly/c62N50SlQBL

$INM

Benzinga Virtual Events: Healthcare & Biotech Breakthroughs Register now and tune into Healthcare & Biotech Breakthroughs — LIVE on Thursday, June 20, 2024 at 11 AM ET!

Benzinga & Breakthroughs Conference is tomorrow at 11am.

InMed's CEO Eric A. Adams joins the conference to speak about new therapeutic approaches in disease and .

Register here to watch: https://www.benzinga.com/events/biotech-breakthroughs-2024/

$INM

Benzinga Virtual Events: Healthcare & Biotech Breakthroughs Register now and tune into Healthcare & Biotech Breakthroughs — LIVE on Thursday, June 20, 2024 at 11 AM ET!

: InMed Advances Therapies Targeting Diseases

BioMedWire writes about InMed's promising preclinical data demonstrating effects in disease and age-related .

Read here: https://ow.ly/RBpb50Sl9NX

$INM

Article: InMed Pharmaceuticals Inc. (NASDAQ: INM) Advances Therapies Targeting Degenerative Diseases - InMed Pharmaceuticals InMed featured in article published in BioMedWire on June 14, 2024 Excerpt: INM-901 is currently being investigated for its potential in treating Alzheimer’s disease. Recent preclinical data showcased its positive pharmacological effects, demonstrating reduced neuroinflammation and improved neuron...

Conference Presentation Replay Now Available!

Watch InMed's presentation at the Emerging Growth Conference on demand here: https://ow.ly/YVvC50Sjl1K

CEO Eric A. Adams give an update on the InMed's pharmaceutical programs and the next steps.

$INM

Replay: InMed Presents at Emerging Growth Conference - InMed Pharmaceuticals Watch InMed’s presentation at the Emerging Growth conference, now available on demand. InMed’s CEO Eric A. Adams presented at Emerging Growth Conference 72 on June 13, 2024. His presentation included an update on the progress of the company’s pharmaceutical programs, including preclinical prog...

June is and Brain Awareness Month.

Did you know 1 in 5 women and 1 in 10 men will develop 's disease in their lifetime?

https://ow.ly/lg9Z50SiTrO

$INM